Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug from lenalidomide for the treatment of multiple myeloma. The company has collaborations with Novo Nordisk to evaluate PharmaShell technology; and Moderna for the development of pharmaceutical products with active substances. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
Frequently asked questions
What sector does Nanexa AB (NANEXA) operate in?
Nanexa AB belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Nanexa AB (NANEXA) current stock price?
As of the latest data, Nanexa AB stock price is SEK 4.70, with a previous close of SEK 4.63. Nanexa AB gained SEK 0.08 in the last trading session, representing a 1.62% increase.
What is Nanexa AB (NANEXA) current market capitalization?
Nanexa AB market cap is approximately 868.50 million.
What is Nanexa AB (NANEXA) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.09.
What is Nanexa AB (NANEXA) EBITDA?
Nanexa AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -10.23 million.
Does Nanexa AB (NANEXA) pay dividends?
No. Nanexa AB does not pay a dividend.
What is Nanexa AB (NANEXA) beta (volatility) score?
Nanexa AB has a beta of 1.725, suggesting it is more volatile than the market.
